Obiettivo Inflammatory Bowel Disease (IBD) covers a cluster of disorders characterized by chronic intestinal inflammation which affects approximately 0.2% of the global human population. Current treatment options often fail, are marred by side-effects and undergoing regular endoscopy to monitor and manage the disease is often a burden to the patient.In this study we aim to:1. Develop a novel treatment for IBD, using the recently described anti-inflammatory effects of agonists capable of selectively activating the Farnesoid X nuclear Receptor (FXR) as a pharmaceutical lead.2. Develop a non-invasive diagnostic tool using well-described changes in the gut microbiome of people affected with IBD as a marker to diagnose and monitor disease progression or remission in stool samples.In order to achieve these objectives we will develop 2 novel biological high-throughput screening assays (luciferase- and cofactor interaction-based) with which we can assay selective activity of FXR. These screening assays will be dictated by fundamental scientific insights in FXR-mediated activity and signal transduction. Meanwhile, a new non-invasive microbiome-based diagnostic tool will be generated and validated using feces from well-defined patients with IBD. Ultimately, this project will culminate in proof of principle using first-in-men clinical trials to demonstrate that the anti-inflammatory activity of FXR agonists can be used to treat IBD successfully in vivo.As illustrated above, the development of a new IBD-treatment option and the validation of a novel diagnostic tool require the input of several domains of scientific knowledge, such as medicine, microbiome-genetics, pharmacology and molecular biology. The free flow of ideas between disciplines and unfettered access to specialist expertise will greatly speed up the development of these novel approaches to the treatment and diagnosis of IBD. Campo scientifico medical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasenatural sciencesbiological sciencesmicrobiologymedical and health sciencesbasic medicinepharmacology and pharmacynatural sciencesbiological sciencesmolecular biology Programma(i) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Argomento(i) FP7-PEOPLE-2013-IAPP - Marie Curie Action: "Industry-Academia Partnerships and Pathways" Invito a presentare proposte FP7-PEOPLE-2013-IAPP Vedi altri progetti per questo bando Meccanismo di finanziamento MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP) Coordinatore UNIVERSITAIR MEDISCH CENTRUM UTRECHT Contributo UE € 806 692,50 Indirizzo HEIDELBERGLAAN 100 3584 CX Utrecht Paesi Bassi Mostra sulla mappa Regione West-Nederland Utrecht Utrecht Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Judith Kohnhorst (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Partecipanti (2) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto TES PHARMA SRL Italia Contributo UE € 383 018,32 Indirizzo CORSO VANNUCCI 47 06121 Perugia Mostra sulla mappa Regione Centro (IT) Umbria Perugia Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Janet Robertson (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato ENTEROME SA Francia Contributo UE € 296 389,18 Indirizzo AVENUE LEDRU ROLLIN 94/96 75011 PARIS Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Marie-Laure Bouttier (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato